Trial Profile
Phase I Study of Neoadjuvant Nivolumab in Patients With Non-metastatic High-risk Clear Cell Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 01 May 2023 Results presented at the 118th Annual Meeting of the American Urological Association.
- 18 Feb 2023 Results assessing Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma presented at the 2023 Genitourinary Cancers Symposium
- 10 Jun 2020 Status changed from active, no longer recruiting to completed.